| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Chief Legal Officer, Sec | See Remarks
2 companies
Jennifer J Rhodes is See Remarks at ELTX and has filed Form 4s across 2 companies. Jennifer J Rhodes's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $278K at current prices.
Historically, Jennifer J Rhodes's trades have earned a strong insider score of 93/100 across 13 rated trades. Over a 12-month horizon, all 11 of those trades were profitable, with an average 12-month return of +86.5%.
The biggest single holding is ACAD (~$232K) as EVP, Chief Legal Officer, Sec. The ACAD filings lean toward selling, a net 10,794 shares.
Jennifer J Rhodes has 19 Form 4 filings on record from February 2021 to March 2026, across 2 companies: EVP, Chief Legal Officer, Sec at ACADIA Pharmaceuticals (ACAD), 2024–2026; Elicio Therapeutics (ELTX), 2021–2022.
The 25 reported transactions were 14 open-market sales, 9 option or other derivative awards and 2 option exercises.
Counted by filing, the open-market trades come to no purchases and 14 sales worth about $307K.
The largest open-market sale was 6,950 shares of ACAD at an average $23.38 on February 9, 2026, about $162K.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | ACAD Acadia Pharmaceuticals Inc. | EVP, Chief Legal Officer, Sec | Sale+OE | 3,844 | $21.47 | $82,530.68 | -25.4% | +2.7% | - | |
| Feb 9, 2026 | ACAD Acadia Pharmaceuticals Inc. | EVP, Chief Legal Officer, Sec | Sale+OE | 6,950 | $23.38 | $162,491.00 | -47.7% | -6.1% | - | |
| Dec 14, 2021 | ELTX Elicio Therapeutics, Inc. | See Remarks | Sell | 451 | $2.42 | $1,090.11 | -1.5% | -26.8% | -65.5% | |
| Nov 15, 2021 | ELTX Elicio Therapeutics, Inc. | See Remarks | Sell | 433 | $4.40 | $1,905.20 | -1.4% | -49.2% | -79.8% | |
| Oct 14, 2021 | ELTX Elicio Therapeutics, Inc. | See Remarks | Sell | 430 | $8.65 | $3,719.50 | -1.4% | -68.3% | -88.2% | |
| Sep 14, 2021 | ELTX Elicio Therapeutics, Inc. | See Remarks | Sell | 430 | $10.64 | $4,575.20 | -1.3% | -76.4% | -88.9% | |
| Aug 16, 2021 | ELTX Elicio Therapeutics, Inc. | See Remarks | Sell | 445 | $10.68 | $4,752.60 | -1.4% | -59.2% | -90.0% | |
| Jul 21, 2021 | ELTX Elicio Therapeutics, Inc. | See Remarks | Sell | 432 | $10.94 | $4,726.08 | -1.3% | -25.2% | -90.8% | |
| Jul 14, 2021 | ELTX Elicio Therapeutics, Inc. | See Remarks | Sell | 431 | $11.01 | $4,745.31 | -1.3% | -16.9% | -89.9% | |
| Jun 14, 2021 | ELTX Elicio Therapeutics, Inc. | See Remarks | Sell | 427 | $13.27 | $5,666.29 | -1.3% | -17.7% | -87.9% |